Yttrium-90 Radiolabeled Anti-Tac Antibody
Leukemia, T-Cell
National Cancer Institute (NCI)radiopharmaceuticalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Leukemia, T-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE Children's Oncology Group | Phase 2 | B |
(+)-VINCRISTINE Children's Oncology Group | Phase 2 | B |
Cyclophosphamide Xinqiao Hospital of Chongqing | Phase 2 | B |
PEGASPARGASE Children's Oncology Group | Phase 2 | B |
Cytosin-Arabinosid Children's Oncology Group | Phase 2 | B |
View all 29 →
Same molecule, other indications
Yttrium-90 Radiolabeled Anti-Tac Antibody is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →